Your session is about to expire
← Back to Search
Prostate SBRT for Prostate Cancer
Study Summary
This trial is studying the maximum tolerated dose and side effects of stereotactic body radiation therapy in people with a local recurrence of prostate cancer after radiation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer markers went up within a year after finishing radiotherapy.My PSA level is 20 ng/dL or higher, and I may not have had a specific scan.I have severe bowel or bladder issues from past radiation.I can take care of myself but might not be able to do heavy physical work.I have inflammatory bowel disease.I have active Lupus or active scleroderma.My cancer has spread to distant parts of my body, but not to areas close to my prostate.I do not have any health or mental conditions that could affect the study.I have severe claustrophobia that doesn't improve with anxiety medication.My prostate cancer came back after radiation treatment.I am 18 years old or older.My PSA levels rose by at least 2 ng/dL after radiation therapy.I need long-term blood thinners, but not just low dose aspirin.I am HIV positive and on medication that increases sensitivity to radiation.I have had surgery to remove my prostate.
- Group 1: Cohort 2, Level 1, Arm 2 - Prostate and Tumor Irradiation
- Group 2: Cohort 1, Level 1, Arm 1: Tumor Irradiation
- Group 3: Cohort 1, Level 2, Arm 1 - Tumor Irradiation
- Group 4: Cohort 2, Level 2, Arm 2 - Prostate and Tumor Irradiation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any past experiments that have investigated the efficacy of Tumor Irradiation?
"At present, there are 18 active clinical studies exploring Tumor Irradiation and none of them have progressed to Phase 3. Although the preponderance of these investigations take place in Baltimore, Maryland, research into this topic is conducted in 27 different locations worldwide."
Is Tumor Irradiation a safe method of treatment for individuals?
"Tumor Irradiation received a score of 1, as there is still limited data available on its safety and efficacy. This evaluation was conducted by our team at Power due to the fact that this trial has not yet progressed beyond Phase 1."
Is there still capacity for participants in this medical experiment?
"According to clinicaltrials.gov, the current search for participants is ongoing and began on July 5th 2018 with its most recent update being November 24th 2022."
How many participants are engaging in this experiment?
"Affirmative. According to clinicaltrials.gov, enrollment for this health research is active and ongoing; the trial was first announced on July 5th 2018 with a recent update occurring November 24th 2022. The experiment hopes to involve 46 people at one locale."
Under what conditions is Tumor Irradiation typically employed?
"Elevated serum prostate specific antigen (PSA) can be managed with tumor irradiation. In addition, this treatment option is also suitable for suspected metastases, positron emission tomography scans, and recurring cases of prostate cancer."
Share this study with friends
Copy Link
Messenger